GT Biopharma, Inc. (GTBP)
NASDAQ: GTBP · Real-Time Price · USD
0.4650
-0.0101 (-2.13%)
At close: Mar 25, 2026, 4:00 PM EDT
0.4600
-0.0050 (-1.08%)
After-hours: Mar 25, 2026, 4:41 PM EDT
GT Biopharma Employees
GT Biopharma had 1 employees as of December 31, 2025. The number of employees did not change compared to the previous year.
Employees
1
Change (1Y)
n/a
Growth (1Y)
n/a
Revenue / Employee
n/a
Profits / Employee
-$34,449,000
Market Cap
14.51M
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) | Full-Time | Part-Time |
|---|---|---|---|---|---|
| Dec 31, 2025 | 1 | 0 | - | 1 | 0 |
| Dec 31, 2024 | 1 | -1 | -50.00% | 1 | 0 |
| Dec 31, 2023 | 2 | 0 | - | 2 | 0 |
| Dec 31, 2022 | 2 | -6 | -75.00% | 2 | 0 |
| Dec 31, 2021 | 8 | 5 | 166.67% | 8 | 0 |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
Related Stocks
| Company Name | Employees |
|---|---|
| IO Biotech | 78 |
| IN8bio | 17 |
| Cocrystal Pharma | 11 |
| Cellectar Biosciences | 11 |
| Intensity Therapeutics | 7 |
| Phio Pharmaceuticals | 6 |
| AEON Biopharma | 5 |
| Jupiter Neurosciences | 4 |
GTBP News
- 23 days ago - GT Biopharma Reports Full Year 2025 Financial Results - GlobeNewsWire
- 5 weeks ago - GT Biopharma to Present at the Centurion One Capital 9th Annual Toronto Growth Conference - GlobeNewsWire
- 7 weeks ago - GT Biopharma Announces FDA Clearance of Investigational New Drug (IND) Application for GTB-5550 TriKE®, a B7-H3-Targeted Natural Killer (NK) Cell Engager for Solid Tumors Expressing B7-H3 - GlobeNewsWire
- 2 months ago - GT Biopharma Announces IND Submission for GTB-5550 TriKE®, a B7-H3-targeted natural killer (NK) cell engager for B7-H3 expressing solid tumor cancers - GlobeNewsWire
- 2 months ago - EXCLUSIVE: GT Biopharma Plans 2026 Trial For New Cancer Treatment - Benzinga
- 3 months ago - Immunotherapies Replacing Chemotherapy as Blood Cancer Market to Hit $13B by 2030 - PRNewsWire
- 4 months ago - GT Biopharma, Inc. (NASDAQ:GTBP) Offers Near-Term Catalyst Opportunity with Advancing Phase 1 Trials - Accesswire
- 4 months ago - GT Biopharma Reports Third Quarter 2025 Financial Results and Provides Corporate Update - GlobeNewsWire